NYSEAMERICAN:STXS Stereotaxis (STXS) Stock Price, News & Analysis $2.81 +0.01 (+0.36%) Closing price 09/19/2025 04:10 PM EasternExtended Trading$2.85 +0.04 (+1.57%) As of 09/19/2025 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestBuy This Stock About Stereotaxis Stock (NYSEAMERICAN:STXS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Stereotaxis alerts:Sign Up Key Stats Today's Range$2.77▼$2.8650-Day Range$2.19▼$2.9052-Week Range$1.54▼$3.05Volume714,619 shsAverage Volume332,757 shsMarket Capitalization$255.91 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Stereotaxis, Inc. is a medical device company that develops and commercializes robotic magnetic navigation systems for use in electrophysiology procedures. Its core technology leverages precisely controlled magnetic fields to guide ultra-thin, magnetically enabled catheters through the vascular system, allowing physicians to perform complex cardiac ablation and diagnostic procedures with enhanced precision and stability. This platform aims to reduce procedure times and radiation exposure for both patients and clinical staff. The company’s flagship offering, the Niobe Magnetic Navigation System, integrates with a variety of catheter types and electrophysiology mapping systems to support treatment of arrhythmias such as atrial fibrillation and ventricular tachycardia. In addition to the Niobe platform, Stereotaxis has introduced the Vdrive Robotic™ system and the EPOCH® solution, which further automate catheter control and sheath deflection to streamline workflow in the electrophysiology lab. Stereotaxis also offers training, installation and technical support services to help facilities adopt and optimize use of its robotic navigation technology. Founded in 1997 and headquartered in St. Louis, Missouri, Stereotaxis has installed systems at leading hospitals and cardiac centers across North America, Europe, the Middle East and Asia-Pacific. The company maintains strategic collaborations with key electrophysiology mapping and imaging partners to advance integration and clinical data collection. Stereotaxis is led by President and Chief Executive Officer Jim Corriveau, whose team brings extensive experience in medical device innovation, regulatory affairs and global product commercialization.AI Generated. May Contain Errors. Read More Stereotaxis Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks13th Percentile Overall ScoreSTXS MarketRank™: Stereotaxis scored higher than 13% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Stereotaxis. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Stereotaxis are expected to grow in the coming year, from ($0.26) to ($0.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Stereotaxis is -9.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Stereotaxis is -9.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioStereotaxis has a P/B Ratio of 40.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Stereotaxis' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.99% of the float of Stereotaxis has been sold short.Short Interest Ratio / Days to CoverStereotaxis has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in Stereotaxis has recently decreased by 13.83%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldStereotaxis does not currently pay a dividend.Dividend GrowthStereotaxis does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.99% of the float of Stereotaxis has been sold short.Short Interest Ratio / Days to CoverStereotaxis has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in Stereotaxis has recently decreased by 13.83%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows1 people have added Stereotaxis to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Stereotaxis insiders have not sold or bought any company stock.Percentage Held by Insiders17.77% of the stock of Stereotaxis is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions45.35% of the stock of Stereotaxis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Stereotaxis' insider trading history. Receive STXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Stereotaxis and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. STXS Stock News HeadlinesISRG's SP Stapler: A Game Changer for Colorectal and Thoracic Procedures?September 3, 2025 | msn.comSTXS Launches First U.S. Robotic HD Mapping With MAGiC SweepSeptember 3, 2025 | msn.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.September 21 at 2:00 AM | American Alternative (Ad)First US Commercial Robotic HD Mapping Procedures Successfully Completed with MAGiC Sweep CatheterSeptember 2, 2025 | globenewswire.comStereotaxis to Present at Upcoming Investor ConferencesSeptember 2, 2025 | globenewswire.comStereotaxis Technology to be Featured at Heart Rhythm Society’s HRX 2025August 28, 2025 | markets.businessinsider.comStereotaxis Technology to be Featured at Heart Rhythm Society's HRX 2025August 28, 2025 | globenewswire.comStereotaxis, Inc. (STXS) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comSee More Headlines STXS Stock Analysis - Frequently Asked Questions How have STXS shares performed this year? Stereotaxis' stock was trading at $2.29 at the beginning of 2025. Since then, STXS stock has increased by 22.7% and is now trading at $2.81. How were Stereotaxis' earnings last quarter? Stereotaxis Inc. (NYSEAMERICAN:STXS) issued its earnings results on Monday, November, 11th. The company reported ($0.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by $0.03. The business had revenue of $9.20 million for the quarter, compared to analyst estimates of $6.80 million. Stereotaxis had a negative net margin of 73.43% and a negative trailing twelve-month return on equity of 440.00%. Read the conference call transcript. Who are Stereotaxis' major shareholders? Stereotaxis' top institutional shareholders include Geode Capital Management LLC (1.72%), Warberg Asset Management LLC (1.40%), Prescott Group Capital Management L.L.C. (1.32%) and State of Wyoming (0.43%). View institutional ownership trends. How do I buy shares of Stereotaxis? Shares of STXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Stereotaxis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Stereotaxis investors own include Tesla (TSLA), Advanced Micro Devices (AMD), NVIDIA (NVDA), Intel (INTC), Meta Platforms (META), JPMorgan Chase & Co. (JPM) and Netflix (NFLX). Company Calendar Last Earnings11/11/2024Today9/21/2025Next Earnings (Estimated)11/10/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNYSEAMERICAN:STXS CIK1289340 Webwww.stereotaxis.com Phone(314) 678-6100Fax314-678-6159Employees130Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$24.05 million Net Margins-73.43% Pretax Margin-73.43% Return on Equity-440.00% Return on Assets-50.62% Debt Debt-to-Equity RatioN/A Current Ratio1.06 Quick Ratio0.59 Sales & Book Value Annual Sales$26.92 million Price / Sales9.51 Cash FlowN/A Price / Cash FlowN/A Book Value$0.07 per share Price / Book40.14Miscellaneous Outstanding Shares91,070,000Free Float74,888,000Market Cap$255.91 million OptionableNot Optionable Beta1.61 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NYSEAMERICAN:STXS) was last updated on 9/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stereotaxis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stereotaxis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.